Strain of HIV virus found in monkeys is cleared by vaccine
Vaccine could be used on humans in clinical trials within two years
Heather Saul is a digital reporter for The Independent, currently working on the People desk. She has written news and features across a number of topics, paying particular attention to the activities of Isis and events in Iraq, Syria, Iran and Saudi Arabia.
Thursday 12 September 2013
A vaccine designed to tackle SIV, the monkey equivalent of HIV, may have successfully cleared the virus from infected animals, paving the way for research into a HIV vaccine for humans.
It was previously thought that both the human and simian immunodeficiency viruses could be managed with antiretroviral therapies, but not eradicated.
However, a study published in the science journal Nature showed that of 16 monkeys exposed to the virus who were injected with a vaccine, nine appeared to be able to clear their body of the disease.
US researchers from the Vaccine and Gene Therapy Institute at Oregon Health and Science University are now hoping to use a similar approach to test for a vaccine equivalent in humans.
The team examined a strain of the virus called SIVmac239, which is up to 100 times more deadly than HIV.
Researchers first inoculated monkeys with the vaccine and then exposed them to SIV. The virus did not spread in over half of the inoculated monkeys, which usually die within two years of being infected.
The vaccine used a modified version of the cytomegalvirus (CMV), which belongs to the herpes family, to sweep through the monkey body and encourage the immune system to fight off SIV.
After being exposed to the virus, some monkey bodies began to respond by searching out and destroying signs of SIV. They remained clear up to three years after first being inoculated.
Prof. Louis Picker told the BBC: “It's always tough to claim eradication - there could always be a cell which we didn't analyse that has the virus in it. But for the most part, with very stringent criteria... there was no virus left in the body of these monkeys.”
However, he said the team were still trying to determine why the vaccine was only successful in nine monkeys.
“It could be the fact that SIV is so pathogenic that this is the best you are ever going to get", he explained.
“There is a battle going on, and half the time the vaccine wins and half the time it doesn't.”
Now, the team want to examine if the same technique could be developed and made safe enough to be successful in humans. Clinical human trials could start within two years if the vaccine is approved and the team receive permission from regulatory bodies, Prof Picker added.
- 2 Watch the Supermoon live: How to see the brightest Moon of the year tonight
- 3 Hulk Hogan wants to be Donald Trump's running mate in the US Presidential election
Caitlyn Jenner car crash: Driver who died in collision sued by surviving passengers for $18.5m
Watch the Supermoon live: How to see the brightest Moon of the year tonight
Hulk Hogan wants to be Donald Trump's running mate in the US Presidential election
Blood Moon and Supermoon: September to bring brightest – and dimmest – full Moon of the year on same night
Turkey duped the US, and Isis reaps rewards
Climate change: 2015 will be the hottest year on record 'by a mile', experts say
'Women only' train carriages: Jeremy Corbyn unveils radical move to tackle public harassment
Black holes are a passage to another universe, says Stephen Hawking
Iain Duncan Smith 'should resign over disability benefit death figures', says Jeremy Corbyn
Tony Blair attacks Jeremy Corbyn's 'Alice In Wonderland' politics
Theresa May says jobless migrants should be banned from entering the UK
£28000 - £37000 per annum: Recruitment Genius: This is an opportunity to join ...
£22000 - £29000 per annum: Recruitment Genius: This company's mission is to ma...
£13832 per annum: Recruitment Genius: This 5 star leisure destination on the w...
£20000 - £32000 per annum: Recruitment Genius: A Sales Account Manager is requ...